Rapid-response vaccines - Does DNA offer a solution?

Nature Biotechnology

Volumn 23, Issue 9, 2005, Pages 1059-1062

  Forde, Gareth M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

INFECTIOUS AGENTS; INFLUENZA PANDEMICS;

VACCINES;

ANTIVIRUS AGENT; ATORVASTATIN; DNA VACCINE; INFLUENZA VACCINE; PLASMID DNA; RECOMBINANT VACCINE; SMALLPOX VACCINE;

AUTOIMMUNE DISEASE; AVIAN INFLUENZA; BIOTECHNOLOGY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE TRANSMISSION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG PACKAGING; DRUG PURIFICATION; DRUG QUALITY; FOOD AND DRUG ADMINISTRATION; GENETIC ENGINEERING; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINATION; VACCINE PRODUCTION; VIRUS STRAIN; WEST NILE FLAVIVIRUS;

ANIMALS; DISEASE OUTBREAKS; DNA; GENETIC ENGINEERING; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; PLASMIDS; TIME FACTORS; VACCINATION; VACCINES; VACCINES, DNA; VIROLOGY; WORLD HEALTH;

AVES; VARIOLA VIRUS; WEST NILE VIRUS;

EID: 27144509741     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0905-1059     Document Type: Review

References (30)

1. Institute of Medicine. Forum on Microbial Threats, Board on Global Health. The Threat of Pandemic Influenza: Are We Ready? (US National Academy of Sciences, Washington, DC, 2004).
2. http://www.who.int/csr/disease/avian_influenza/country/en/
3. World Health Organization. Epidemic Alert and Response: Vaccines for Pandemic Influenza. Summary Report (WHO, Geneva, 2004).
4. Check, E. Nature 435, 404-406 (2005).
5. Plotkin, S.A. Health Affairs 24, 631-634 (2005)
6. Sellers, L.J. Pharmaceutical Executive 24, 60-70 (May 2004).
7. Global Alliance for Vaccines and Immunization. Immunization Financing Options. (GAVI, Geneva, Switzerland, 2004) http://www.who.int/ immunization_financing/options/briefcase/en/.
8. Wahlberg, D. & Seabrook, C. Flu vaccine production system shaky. New York Times Syndicate (October 10, 2004).
9. Subbarao, K. et al. Virology 305, 192-200 (2003).
10. Lipatov, A.S., Webby, R.J., Govorkova, E.A., Krauss, S. & Webster, R.G. J. Infect. Dis. 191, 1216-1220 (2005).
11. Webby, R.J. et al. Lancet 363, 1099-1103 (2004).
12. Hehme, N., Engelmann, H., Kuenzel, W., Neumeier, E. & Saenger, R. Virus Res. 103, 163-171 (2004).
13. Wolff, J.A. et al. Science 247, 1465-1468 (1990).
14. Michel, M.L. et al. Proc. Natl. Acad. Sci. USA 92, 5307-5311 (1995).
15. Davis, H.L. Curr. Opin. Biotechnol. 8, 635-640 (1997).
16. Diogo, M.M. et al. J. Gene Med. 3, 577-584 (2001).
17. Johansen, P. et al. Immunol. Lett. 90, 81-85 (2003).
18. Bouchie, A. Nat. Biotechnol. 21, 11 (2003).
19. Ulmer, J.B. et al. Science 259, 1745-1749 (1993).
20. Weiss, R. West Nile's widening toll. Washington Post (p A01, 28 December 2002). http://www.washingtonpost.com/wp-dyn/articles/A45800-2002Dec27.html
21. Scherman, D. Bulletin de I Academie Nationale de Medecine 185, 1683-1697 (2001).
22. McDonnell, W.M. & Askari, F.K. N. Engl. J. Med. 335, 42-45 (1996).
23. UK Vaccine Industry Group. Production: How are Vaccines Made? (Association of the British Pharmaceutical Industry, London, UK, 2004) http://www.uvig.org/
24. http://www.aldevron.com/pdf/West_Nile_Virus_Vaccine.pdf (2003).
25. Boehringer Ingelheim. Method and device for isolating and purifying a polynucleotide of interest on a manufacturing scale. UK Patent WO03051483 (2003).
26. Chase, H.A. J. Mol. Recogn. 11, 217-221 (1998).
27. Woodgate, J., Palfrey, D., Nagel, D.A., Hine, A.V. & Slater, N.K.H. Biotechnol. Bioeng. 79, 411-418 (2002).
28. Agrawal, S. & Kandimalla, E.R. Nat. Biotechnol. 22, 1533-1537 (2004).
29. Journal of Gene Medicine. Gene Therapy Clinical Trials Worldwide (New York, John Wiley and Sons, 2004). http://www.wiley.co.uk/genetherapy/clinical/
30. World Health Organization. Influenza Pandemic Preparedness and Response (WHO, Geneva, 2005). http://www.who.int/gb/ebwha/pdf_files/EB115/B115_44-en.pdf